Dana-Farber Cancer Institute | Strategic Alliance Partners

September 14, 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

September 09, 2025

Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

September 08, 2025

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

September 07, 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

September 04, 2025

Jacob Sands, MD, discusses ways to manage the toxicities associated with the DLL3 inhibitor tarlatamab in the treatment of patients with SCLC.

September 02, 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

September 01, 2025

Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.

September 01, 2025

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.

August 31, 2025

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

August 28, 2025

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

August 27, 2025

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

August 21, 2025

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

August 11, 2025

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

August 11, 2025

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

August 08, 2025

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

August 07, 2025

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

August 04, 2025

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

August 03, 2025

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

July 29, 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss ongoing research to watch in ovarian cancer.

July 25, 2025

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.